Disseminated Kaposi sarcoma following COVID-19 in a 61-year-old Albanian immunocompetent man: a case report and review of the literature

Giulia Gardini1,2*, Silvia Odolini1, Giovanni Moioli1, Dorothea Angela Papalia1,2, Vittorio Ferrari2,3, Alberto Matteelli1,2 and Silvio Caligaris1

Abstract

Background: COVID-19 and its related anti-inflammatory treatment (steroids, immunomodulators) may induce the reactivation of latent bacterial, parasitic, and viral infections. According to our knowledge, no case of disseminated HHV-8-related Kaposi sarcoma (KS) after COVID-19 and its treatment has been described so far. Only one case of cutaneous KS concurrently with COVID-19 has been previously reported.

Case presentation: We describe a case of disseminated KS in a 61-year-old immunocompetent Albanian man after hospitalization for COVID-19.

Methods for literature research: We used PubMed as biomedical database for the literature research. We selected keyword combinations including “Kaposi sarcoma,” “HHV-8,” “immunocompetent,” “COVID-19,” “SARS-CoV-2,” and “steroids.” No time or language limitation was set. Titles and abstracts of selected articles were systematically screened. Articles were included in the examination if they were published under free access through the digital library of the University of Brescia (Italy), and provided full text. Articles were excluded if the topic was beyond the aim of our study. Finally, we selected 15 articles.

Results: We describe a case of KS in COVID-19 patient and postulate that Interleukin-6 (IL-6) activity and steroid-induced immunodeficiency may play a major role in KS emergence. No published case of disseminated KS following COVID-19 in otherwise healthy individuals was found through the systematic literature review, despite the high incidence of COVID-19 in areas with medium–high prevalence of HHV-8 infection. This observation might be explained by the role of individual genetic susceptibility factors.

Conclusions: SARS-CoV-2 infection and its treatment may lead to reactivation of several latent infections, including HHV-8 and its related clinical syndrome, Kaposi sarcoma.

Keywords: HHV-8, Kaposi sarcoma, COVID-19, Latent infection, Reactivation

*Correspondence: giulia.gardini90@gmail.com
1 ASST Spedali Civili Hospital, University Division of Infectious and Tropical Diseases, Brescia, Italy
Full list of author information is available at the end of the article
viruses, reactivation of HHV-1, VZV, HHV-6, HHV-7, and EBV have been reported [3–5].

According to our knowledge, only one case of cutaneous HHV-8-related KS after COVID-19 has been described so far [6]. A woman with previous history of KS experienced new skin relapse during COVID-19 (histological confirmation). No information about the immune status of the patient, the clinical severity of COVID-19, and concomitant drugs were reported by authors.

KS is a tumor of lymphatic and vascular endothelial cells, of which 4 types are distinguished based on risk groups, clinical presentation, and prognosis [7]. HHV-8 (re)active infection is a fundamental element to develop the sarcoma, but normally host factors contribute to the pathogenesis, in particular, genetic susceptibility (e.g., in African or endemic KS) and immune status (e.g., AIDS-related KS) [8]. The visceral involvement is typically observed in immunosuppressed individuals (e.g., AIDS, solid organ transplant recipients) and African children. On the contrary, immunocompetent subjects usually experience localized cutaneous lesions.

We here describe a case of disseminated KS in an immunocompetent 61-year-old man after hospitalization for COVID-19.

Case presentation
On February 9, 2021, a 61-year-old Albanian man was admitted to our division due to SARS-CoV-2 pneumonia. Co-morbidities were diabetes and arterial hypertension, and co-medications were metformin, bisoprolol, and ACE inhibitor. After a few days, he was transferred to Intensive Care Unit (ICU) for respiratory failure. He was put on invasive ventilation and remained intubated for 4 days. In the meantime, he was treated with remdesivir, high-dose steroids (minimum dosage was iv dexamethasone 6 mg daily; maximum dosage was iv dexamethasone 20 mg daily), and antibiotics (ceftriaxone, azithromycin). Blood exams showed transient viral-induced lymphopenia for 10 days (minimum value 540 cells/μL). HIV test resulted negative. On February 26, 2021, he was transferred to another clinic for neuromotor rehabilitation.

Co-medications were the same as before hospitalization, except for subcutaneous enoxaparin due to jugular thrombosis in the site of previous central venous catheterization. Steroid therapy was administered for a total of 10 days. No signs or symptoms suspected of other infections were present at that time.

At the beginning of March, still in the rehabilitation facility, the patient experienced high fever and abdominal pain and the laboratory results showed anemia, thrombocytopenia, and high inflammatory markers (white blood cells 15,000 cells/μL, C-reactive protein 111 mg/L with normal value <5 mg/L). Piperacillin/tazobactam and levofloxacin were started empirically, while enoxaparin was suspended. After a week, the clinical condition of the patient further deteriorated; thereby, the antibiotic therapy was escalated (meropenem + linezolid). The absence of improvement and the limited diagnostic resources available in the rehabilitation structure led him back to our division at the beginning of April. The following conditions were considered as differential diagnosis: uncontrolled sepsis, reactivation of a latent infection (tuberculosis? cytomegalovirus?), and a de-novo malignant hematological disease. Biochemistry revealed anemia of unclear etiology (no intestinal bleeding, no vitamin or iron deficiency, no hemolysis, no bone marrow dysfunction), increased inflammatory indices, some unspecific alterations in the peripheral smear (thrombocytopenia plus macro-platelets; inflammatory aspect of neutrophils and lymphocytes), and hypergammaglobulinemia (43%—normal range 11–18%). LDH and thyroid function were normal. Peripheral lymphocytic typing presented no clonality. Microbiological researches resulted negative (blood cultures, sputum for bacteria, fungi, and alcohol–acid-resistant bacilli, plasmatic EBV-DNA and Parvovirus B19-DNA, serology for Leishmania, T. gondii and Bartonella, IGRA test, serum Aspergillus antigen, fecal H. pylori antigen, HBsAg, HCV antibodies) except from a transient and low-level positivity of plasmatic CMV-DNA (658 copies/mL). HIV test was not repeated in this occasion. Autoimmune panel was negative. Neck ultrasound showed multiple non-colligate and partly confluent adenopathies (max. 21 mm). Core needle biopsy of a cervical lymphadenopathy was executed. At the same time a computed tomography (CT) scan of the abdomen was performed with radiological signs of cholecystitis and splenomegaly (about 17 cm). Minor alterations were a mild pleural effusion, ascending colon coprostasis with proximal dilatation, and abdominal and inguinal lymph adenomegalies. Antibiotic treatment (piperacillin/tazobactam, later switched to ertapenem) was resumed and the patient received blood transfusion. After a week we obtained stable apyrexia, a stable hemoglobin level (from 7.8 to 9.5 mg/dL), increasing platelets count (from 37,000 to more than 1,00,000), and normalization of inflammatory markers. He was discharged home with the diagnosis of cholecystitis and para-infectious cytopenia, while awaiting the histological and microbiological results of the lymph node biopsy.

In May, we received an unexpected histological diagnosis of Kaposi sarcoma on the lymph nodal core needle biopsy previously performed (details in Fig. 1) and he was re-admitted to our ward. At physical examination he presented purple skin lesions on his forearms, palms, legs, and palate, that had appeared a few days before. Over the next 24 h, he developed further comparable skin lesions.
on the thorax. Histological diagnosis was re-confirmed on skin and palate biopsies (details in Fig. 1). Endoscopy of the gastrointestinal tract did not identify suspected lesions. Plasmatic HHV-8 DNA was 2306 copies/mL, and the molecular detection on tissue was not performed. No active infection of CMV, EBV, HSV 1–2, and HHV-6 was detected. IgG and IgM for HTLV-1 resulted negative. He remained negative for HCV, HBV, and HIV infections. The full-body CT scan revealed a disseminated disease (lung parenchymal nodules, liver and spleen lesions, deep lymph adenomegalies above and below the diaphragm, inguinal and axillary lymph nodes) (see Fig. 2). Chemotherapy was started.

After three cycles of well-tolerated liposomal doxorubicin, we obtained a partial improvement of skin and mucosal lesions, which appeared decreased in size and thickness.

Methods for literature research
We used PubMed as biomedical database and selected keyword combinations including “Kaposi sarcoma,” “HHV-8,” “immunocompetent,” “COVID-19,” “SARS-CoV-2,” and “steroids.” No time or language limitation was set. Titles and abstracts of selected articles were systematically screened. Articles were included in the examination if they were published under free access through the digital library of the University of Brescia (Italy), and provided full text. Articles were excluded if the topic was beyond the aim of our study. Finally, we selected 15 articles.

Discussion
Disseminated KS is frequently seen in HIV population with low CD4+ cells count or HIV-uninfected patients with other immunosuppressive disorders as transplant recipients.
Our patient had no history nor immunological constellation of immune deficiencies. The only events that may have contributed to reactivate a latent HHV-8 infection were the recent COVID-19 and the administration of high-dose steroids. We conducted a literary search to determine if other similar cases have been reported.

At first, we searched for cases of disseminated KS in immunocompetent individuals (keyword combinations, including “sarcoma Kaposi” and “immunocompetent” and “HHV-8”) and we found only 1 case that had occurred in a 62-year-old man with a history of chronic alcoholism, diabetes, hypertension, and previous smoking [9]. The other results included 3 patients with HHV-8-related hemophagocytic syndrome (HS), but no evidence of KS, in a 61-year-old Taiwanese immunocompetent man [10] and two Italians over sixty years old following steroidal treatment for autoimmune hemolytic anemia [11]. A localized cutaneous KS, started as inguinal lymph node involvement, was reported in a 67-year-old Tunisian hypertensive and diabetic man [12]. 8 cases of cutaneous and/or mucosal KS in immunocompetent individuals were also reported (a 77-year-old Irish man, 2 men under 50 years old of unknown origin, a 55-year-old Afro-American man, 4 Turkish men of whom 3 over 70 years old and 1 of 27 years old) [13–16].

Some of the mentioned articles [8, 9] pointed to the role of IL-6 (Interleukin-6) in the pathogenesis of HHV-8-associated diseases (see Fig. 3). IL-6 production is stimulated by systemic viral infection (e.g., HHV-8, HIV), autoimmune diseases, hematologic disorders of lymphocytes, KS, and even by itself through a paracrine process. It then promotes inflammation and B cell proliferation, favoring B cell malignancies.

IL-6 biological activities and the positive effect of SARS-CoV-2 on its production [17] made us speculate that the underlying event implicated in the development of disseminated KS in our patient could be COVID-19. Leoni et al. [6] also speculated a similar role of IL-6 for their patient. A woman, with past history of KS and hospitalized for COVID-19, presented a concurrent relapse of skin KS. In skin biopsies both viral families (HHV-8, SARS-CoV-2) were detected by transmission electron microscope. Observing the reactivation of several herpesviruses, but not HHV-8, during COVID-19 [3–5], Chen et al. [18] performed an experimental laboratory study to test the effect of SARS-CoV-2 proteins and some anti-COVID-19 drugs (azithromycin, chloroquine, hydroxychloroquine, remdesivir, nafamostat mesylate) on reactivation of HHV-8. They revealed the capacity of both virus and azithromycin to manipulate intracellular signaling pathways toward reactivation of HHV-8 and thereby to favor HHV-8-related diseases as KS.

Steroidal therapy might also have played a role. Using key words combinations, including “steroids” and “Kaposi sarcoma,” we found only a few cases of KS induced by steroids [19–24]. Most of them occurred after long-term use of steroids prescribed for autoimmune or lymphoproliferative disorders; the disease was limited to the skin and partially regressed after steroids reduction or suspension. Visceral involvement was reported in 3
cases (1 case of stomach involvement after administration of steroids for osteoarticular pain, 1 case of intestinal KS in a 21-year-old Ethiopian male who has taken steroids for IgA nephropathy and with a recent diagnosis of Crohn’s disease, 1 case of disseminated KS in a 76-year-old woman with seronegative polyarthritis and idiopathic CD4 lymphocytopenia) [19, 20, 24].

In the light of the reported evidence, our case appears exceptional for several reasons. At first, disseminated KS is extremely rare in immunocompetent individuals. Steroids may induce KS, but generally if they are administered for prolonged period (not a few days as for our patient). Moreover, steroids-induced KS is usually a localized cutaneous or mucosal type. Considering the high incidence of COVID-19 in Italy and the comparable prevalence of latent HHV-8 infection among Italian and Albanian populations [25, 26], we cannot explain why no other cases of KS after COVID-19 have been reported until now. A possible explanation is that our patient may present concomitantly genetic susceptibility factors to develop HHV-8-related disease (not investigated). Further evidences and studies are needed.

Conclusions
Reactivation of latent infections, including HHV-8, should be always considered when evaluating a patient with signs or symptoms of underlying infection and a recent history of COVID-19 and anti-COVID-19 steroids therapy.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
For this study we used the general authorization of the Italian Guarantor for the use of retrospective demographical and clinical data, which have been anonymized and treated according to Italian current laws.

Consent for publication
The patient gave an informed consent for this publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1 ASST Spedali Civili Hospital, University Division of Infectious and Tropical Diseases, Brescia, Italy. 2 University of Brescia, Brescia, Italy. 3 Division of Oncology, ASST Spedali Civili Hospital, Brescia, Italy.

Received: 2 September 2021   Accepted: 8 December 2021
Published online: 20 December 2021

References
1. Marchese V, Crosato V, Gulletta M, Castelnuovo F, Cristini G, Matteelli A, Castelli F. Strongyloides infection manifested during immunosuppressive therapy for SARS-Cov-2 pneumonia. Infection. 2021;49(3):539–42. https://doi.org/10.1007/s15010-020-05122-4 (Epub 2020 Sep 10).
2. Rodríguez-Tajes S, Miralpeix A, Costa J, López-Suñé E, Laguno M, Pocurull A, Lens S, Marínho Z, Forns X. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat. 2021;28(1):89–94. https://doi.org/10.1111/jvh.13410 (Epub 2020 Oct 12).
3. Xu R, et al. Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19. Br J Dermatol. 2020;183:1145–7.
4. Tartari F, et al. Herpes zoster in COVID-19-positive patients. Int J Dermatol. 2020;59:1028–9.
5. Diago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus 6, 7 and Epstein Barr virus reactivation in pityriasis rosea during COVID-19. J Med Virol. 2021;93:1850–1.
6. Leone E, Cerati M, Finzi G, Lombardo M, Sessa F. COVID-19 and HHV-8 first spotted together: an affair under electron microscopy. J Eur Acad Dermatol Venereol. 2021;35(5):e311–2. https://doi.org/10.1111/jdv.17123 (Epub 2021 Feb 5).
7. Krown ES, Chadha Singh J. Classic Kaposi sarcoma: clinical features, staging, diagnosis, and treatment. https://www.upodate.com/contents/classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment?search=kaposi%20sarcoma&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3. Accessed date 7 June 21.
8. Casper C. Disease associations of human herpesvirus 8 infection. https://www.upodate.com/contents/disease-associations-of-human-herpesvirus-infection?search=hhv&source=search_result&selectedTitle=1~78&usage_type=default&display_rank=1. Accessed date 7 June 21.
9. Kim B, Jeon YK, Kim CW. Kaposi sarcoma herpes virus-associated hemophagocytic syndrome complicated by multicentric castleman disease. https://www.upodate.com/contents/kaposi-sarcoma-hemophagocytic-syndrome?search=hhv&source=search_result&selectedTitle=2~78&usage_type=default&display_rank=1. Accessed date 7 June 21.

Fig. 3  Connection between IL-6, HHV-8, and inflammatory/lymphoproliferative disorders

Abbreviations
AIDS: Acquired immune deficiency syndrome; ACE: Angiotensin-converting enzyme; IGRA: Interferon gamma release assay; KS: Kaposi sarcoma; LDH: Lactate dehydrogenase.

Acknowledgements
None.

Authors’ contributions
All the authors clinically managed the patient. GG conducted the literature research. GG, SO, and GM compiled the manuscript. All the authors read and approved the final manuscript.

Funding
This study was not supported by any third-party funding.
disease and Kaposi sarcoma in a HIV-negative immunocompetent patient: an autopsy case. J Korean Med Sci. 2009;24(5):970–4. https://doi.org/10.3346/jkms.2009.24.5.970 (Epub 2009 Sep 24).

10. Li CF, Ye H, Liu H, Du MQ, Chuang SS. Fatal HHV-8-associated hemophagocytic syndrome in an HIV-negative immunocompetent patient with plasmablastic variant of multicentric Castleman disease (plasmablastic microlymphoma). Am J Surg Pathol. 2006;30(1):123–7. https://doi.org/10.1097/01.pas.0000172293.59785.b4.

11. Re A, Facchetti F, Borlenghi E, Cattaneo C, Capucci MA, Ungari M, Barozzi P, Vallenzi D, Potenza L, Torelli G, Rossi G, Luppi M. Fatal hemophagocytic syndrome related to active human herpesvirus-8/Kaposi sarcoma-associated herpesvirus infection in human immunodeficiency virus-negative, non-transplant patients without related malignancies. Eur J Haematol. 2007;78(4):361–4. https://doi.org/10.1111/j.1600-0609.2007.00828.x (Epub 2007 Jan 22).

12. Zoubedi H, Aydi Z, Daroud F, Rachdi I, Koubaa W, Jouini R, Baili L, Debbeche A, Ben Dhaou B, Boussema F. Kaposi’s sarcoma presenting as lymphadenopathy in an immunocompetent patient. Eur J Case Rep Intern Med. 2016;3(7):000493. https://doi.org/10.12890/2016_000493.

13. Florek AG, Eilers D, Armstrong AW. A case of Kaposi sarcoma in an immunocompetent, heterosexual Irish man: a discussion of etiology and viral transmission. Dermatol Online J. 2012;18(10):13. https://doi.org/10.3315/derm.2012.1088.

14. Sikora AG, Shnayder Y, Yee H, DeLacure MD. Oropharyngeal Kaposi sarcoma in related persons negative for human immunodeficiency virus. Ann Otol Rhinol Laryngol. 2008;117(3):172–6. https://doi.org/10.1177/00034840081700303.

15. Hinojosa T, Lewis DJ, Liu M, Garza G, Vangipuram R, Ramos E, Salas-P , Vallerini D, Potenza L, Torelli G, Rossi G, Luppi M. Fatal hemophagocytic syndrome related to active human herpesvirus-8/Kaposi sarcoma-associated herpesvirus infection in human immunodeficiency virus-negative, non-transplant patients without related malignancies. Eur J Haematol. 2007;78(4):361–4. https://doi.org/10.1111/j.1600-0609.2007.00828.x (Epub 2007 Jan 22).

16. Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1–9. https://doi.org/10.1002/rmv.2141. (Epub 2020 Aug 26).

17. Chen J, Dai L, Barrett L, Post SR, Qin Z. SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. bioRxiv. 2020. https://doi.org/10.1101/2020.10.02.324228.

18. Trattner A, Hodak E, David M, Sandbank M. The appearance of Kaposi sarcoma during corticosteroid therapy. Cancer. 1993;72(5):1779–83. https://doi.org/10.1002/1097-0142(19930901)72:5%3c1779::aid-cncr2820720543%3e3.0.co;2-m.

19. Windon AL, Shroff SG. Iatrogenic Kaposi’s sarcoma in a young male with Crohn’s disease and IGA nephropathy: a case report and brief review of the literature. Int J Surg Pathol. 2018;26(3):276–82. https://doi.org/10.1177/1066896917736610 (Epub 2017 Nov 23).

20. Brambilla L, Espósito L, Nazzaro G, Tourlaki A. Onset of Kaposi sarcoma in a young male with Crohn’s disease and IgA nephropathy: a case report and brief review of the literature. Int J Surg Pathol. 2018;26(3):276–82. https://doi.org/10.1177/1066896917736610 (Epub 2017 Nov 23).

21. Htet KZ, Waul M, Edelstein H, Mui S, Cherny S, Leslie K. Primary nasal Kaposi sarcoma in well-controlled HIV-positive patient with normal CD4 count associated with long-term nasal steroid use. Int J STD AIDS. 2021;32(6):582–4. https://doi.org/10.1177/0956462420980644 (Epub 2021 Feb 3).

22. Simeoni S, Puccetti A, Moruzzi S, Tinazzi E, Peteriana D, Lunardi C. Dermatomyositis complicated with Kaposi sarcoma: a case report. Clin Rheumatol. 2007;26(3):440–2. https://doi.org/10.1007/s10067-005-0148-3 (Epub 2006 Jan 26).

23. Schinaia N, Kodja Y, Sarmati L, Andreoni M, Bino S, Quirò S, Rezza G, Prevalence of HHV-8 infection in Albanian adults and association with HBV and HCV. Eur J Epidemiol. 2004;19(S):467–9. https://doi.org/10.1023/b:ejep.0000027358.38997.66.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.